1 recruiting. 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Recruiting 1 |
Follow Appendiceal Cancers: new trials by email Literature Review of Appendiceal Cancers trials Research Report on Appendiceal Cancers
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| NALIRIFOX (Nal-IRI Plus 5-FU/LV Plus Oxaliplatin) as First-Line Treatment for Patients With Advanced Small Intestine and Appendiceal Cancers Patients will be treated with NALIRIFOX (liposomal irinotecan 50 mg/m2 + 5-FU 2400 mg/m2 + LV 400 mg/m2 + oxaliplatin 60 mg/m2, IV) every 2 weeks for 12 months - Advanced Small Intestine Cancer, Appendiceal Cancers | Phase 1 | Recruiting | The Methodist Hospital Research Institute | 22 | 2026-09-18 | 2026-11-03 |
Fluorouracil (1) · Oxaliplatin (1) · irinotecan sucrosofate (1)
The Methodist Hospital Research Institute (1)
United States (1)